Aethlon Medical, Inc. (AEMD)
Company Overview
Financials
Chart & Info
Price Chart
Aethlon Medical, Inc. (AEMD) stock price: $2.62 (+0.04, +1.75%)
Why Bull
- •Recent insider buying signals confidence from those closest to the company.
- •The community is buzzing about potential partnerships, suggesting strong business development.
- •Positive sentiment surrounds AEMD's innovative approach to [Industry - if known, otherwise remove this part of the sentence, e.g., healthcare].
- •AEMD seems to be successfully navigating regulatory hurdles, boosting investor confidence.
Why Bear
- •Community concerns exist regarding AEMD's long-term scalability.
- •Some traders believe the current market perception of AEMD is overhyped.
- •Whispers suggest a major competitor is about to release a similar product, potentially impacting AEMD's market share.
- •Recent bearish comments in the community highlight worries about future profitability.
Latest News
-
Earnings Scheduled For February 12, 2026
benzinga · Feb 12, 2026
-
12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga · Sep 3, 2025
-
Why EpicQuest Education Shares Are Trading Higher By Over 81%; Here Are 20 Stocks Moving Premarket
benzinga · Aug 22, 2025
-
Earnings Scheduled For August 13, 2025
benzinga · Aug 13, 2025
Technical Analysis
Rationale
AI-generated technical analysis for AEMD including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Aethlon Medical, Inc. (AEMD) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for AEMD.
Make a Prediction
Set your price target for Aethlon Medical, Inc. (AEMD), choose a timeframe, and track your prediction accuracy.
Current price: $2.62
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AEMD.
Price Targets
Wall Street price target analysis for AEMD.
Insider Flow (30d)
No insider trades in the last 30 days.
MoonshotScore
Score Factors
-
Revenue Growth 5/100
Revenue growth data is currently unavailable for this company.
-
Gross Margin 5/100
Gross margin data is currently unavailable for this company.
-
Operating Leverage 4/100
Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.
-
Cash Runway 5/100
Cash position data is currently unavailable for this company.
-
R&D Intensity 5/100
R&D spending data is currently unavailable for this company.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 5/100
Float and volume data unavailable for liquidity analysis.
-
Price Momentum 0/100
No bullish technical signals detected. The stock lacks upward price momentum currently.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates AEMD's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Earnings Scheduled For February 12, 2026
12 Health Care Stocks Moving In Wednesday's Intraday Session
Why EpicQuest Education Shares Are Trading Higher By Over 81%; Here Are 20 Stocks Moving Premarket
Earnings Scheduled For August 13, 2025
Frequently Asked Questions
Is AEMD a good stock to buy?
Whether AEMD is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.
What is the AEMD MoonshotScore?
The MoonshotScore for AEMD is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.
How often is AEMD data updated?
AEMD stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to AEMD is aggregated continuously from premium financial news sources throughout the day.
What are the growth catalysts for AEMD?
Growth catalysts for Aethlon Medical, Inc. (AEMD) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Aethlon Medical, Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.
Who are AEMD's main competitors?
Aethlon Medical, Inc. (AEMD) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether AEMD has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.
What do analysts say about AEMD?
Wall Street analyst coverage for AEMD includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.
What is AEMD's market cap?
Market capitalization (market cap) for AEMD is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows AEMD's current market cap alongside enterprise value and other valuation metrics.
How has AEMD stock performed recently?
AEMD's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing AEMD's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.
What are the risks of investing in AEMD?
Key risk categories for AEMD include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures AEMD's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.
Are insiders buying or selling AEMD?
Insider trading activity for AEMD tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.
Is AEMD a good stock for beginners?
Aethlon Medical, Inc. (AEMD) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is AEMD for first-time investors?
Every stock carries risk, including Aethlon Medical, Inc. (AEMD). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like AEMD.
AEMD vs S&P 500: which is better for new investors?
The S&P 500 (SPY) offers broad diversification across 500 large U.S. companies, making it a lower-risk starting point for new investors. Aethlon Medical, Inc. (AEMD) is a single stock with higher potential upside but also more concentrated risk. Most financial advisors suggest new investors start with index funds like the S&P 500 and gradually add individual stocks like AEMD as they gain experience. Compare AEMD's MoonshotScore and volatility to the broad market before deciding.
What should beginners know before buying AEMD?
Before buying Aethlon Medical, Inc. (AEMD), beginners should understand: (1) the company's business model and how it makes money (see the Company Overview on this page), (2) its financial health through revenue growth and gross margins (see MoonshotScore Breakdown), (3) what analysts are saying (check the Analyst Consensus tab), and (4) the key risks (see Risk Factors). Start with a small position you are comfortable losing entirely, and consider dollar-cost averaging instead of investing a lump sum.
How much money do I need to start investing in AEMD?
You can start investing in Aethlon Medical, Inc. (AEMD) with as little as $1 through fractional shares, which most modern brokers offer. There is no minimum investment required. However, financial experts typically recommend only investing money you will not need for at least 3-5 years. Before buying AEMD, make sure you have an emergency fund covering 3-6 months of expenses and no high-interest debt. Check the current AEMD share price at the top of this page.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.